Physician profile
Michael D Flanagan
NPI 1851453252
$5,095.61
in general payments reported to CMS, 2019-2025
40 companies · $1,219 in 2025
The $1,219 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $622 · 2020: $157 · 2021: $13.67 · 2022: $781 · 2023: $1,154 · 2024: $1,149 · 2025: $1,219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,522.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $746.80 | 2019-2025 | |
| Lilly USA, LLC | $468.38 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $447.00 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $369.51 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Daiichi Sankyo INC. | $290.14 | 2019-2025 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $252.78 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $248.97 | 2019-2024 | Jardiance |
| Astellas Pharma US INC | $231.57 | 2019-2024 | Myrbetriq, Veozah |
| Pfizer INC. | $228.47 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $214.42 | 2019-2025 | Belsomra, Lagevrio, Steglatro |
| Amgen INC. | $181.21 | 2019-2025 | Repatha, Otezla, Evenity |
| Novartis Pharmaceuticals Corporation | $174.80 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.51 | 2022-2025 | |
| Axsome Therapeutics, INC. | $121.94 | 2024-2025 | Auvelity |
| Lundbeck LLC | $77.14 | 2025 | Rexulti |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Flanagan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.